COAG — Hemab Therapeutics Holdings, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2114044 ·
Last close
$53.48
Market Cap
$2.50B
52W High
$54.65
52W Low
$23.81
ADV30
402,741
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Mar 2025 | 0 | — | -16,560,000 | -15,306,000 | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$-204,545,000
Inventory
—
Receivables
$1,430,000
ST Investments
$113,671,000
EBIT TTM
$-40,172,000
Pretax Income TTM
$-38,171,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -70,119,000 | -63,913,000 | 194,783,000 | 371,418,000 | — | -61,475,000 |
| Dec 2024 | 0 | -50,383,000 | -48,707,000 | 96,278,000 | 211,551,000 | — | -45,592,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.54
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MEOBF | MESOBLAST LTD | $2.45B | $1.89 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.71B | $10.59 | — |
| KOD | Kodiak Sciences Inc. | $2.72B | $43.41 | — |
| VCEL | Vericel Corp | $2.29B | $44.73 | — |
| BEAM | Beam Therapeutics Inc. | $2.76B | $26.71 | — |
News headlines (Yahoo Finance, 1h cache)
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-11 11:00 · Yahoo
Biotech IPO Gains Crush AI Listings With Standout 55% Return
2026-07-21 12:35 · Yahoo
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
2026-07-14 11:45 · Yahoo
Sector Update: Healthcare Stocks Advance Late Afternoon
2026-07-13 19:34 · Yahoo
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
2026-07-12 10:28 · Yahoo
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
2026-06-26 13:00 · Yahoo
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
2026-06-09 03:03 · Yahoo
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-27 12:00 · Yahoo
Hemab Therapeutics Reports First Quarter 2026 Financial Results
2026-05-21 11:00 · Yahoo
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-05-04 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.